David Bentley on Involvement in Genomics: Current Research
  David Bentley     Biography    
Recorded: 14 May 2004

At the moment clearly my own focus is primarily to look at how the human genome sequence varies within individuals, from a point of view of examining the pressures, the forces which shape human populations, something about which I know very little, but it’s very interesting. It appeals to me because it remains studying DNA sequence as opposed to intracellular function and other aspects like that. The other area is to work very directly on—tangible health benefits from the human genome. How this information really can be used in the medical arena.

David Bentley, molecular biologist and geneticist, is currently Vice President and Chief Scientist of DNA Sequencing at Illumina, Inc., a commercial developer of genetic analysis tools and systems.

Educated at the University of Cambridge (M.A. in biochemistry) and the University of Oxford (Ph. D.), Dr. Bentley was a postdoctoral fellow, lecturer, and senior lecturer at Guy's and St. Thomas's Hospital in London from 1991 to 1993 where he studied mutations that cause genetic diseases, and a Senior Lecturer in the Division of Medical & Molecular Genetics at the University of London.

In 1993 he was brought to Sanger Centre (now known as Wellcome Trust Sanger Institute) as a founding member and head of human genetics by his mentor, John Sulston. Dr. Bentley led Sanger in their major contributions to the Human Genome Project, The Single Nucleotide Polymorphisms (SNP) Consortium, and the International Haplotype Mapping (HapMap) Project. Dr. Bentley left Wellcome in 1985 to join commercial sequencer, Solexa, Inc., as Chief Scientist where he was responsible for the Company’s DNA sequencing applications development and projects. Solexa was acquired by Illumina in 2007.